The Leukemia & Lymphoma Society has announced a $10 million gift from the Florida-based Harry T. Mangurian Jr. Foundation in support of a clinical trial focused on acute myeloid leukemia (AML), a deadly blood cancer.
The gift will be used to expand LLS's precision-medicine-based Beat AML Master Clinical Trial, a collaboration involving multiple pharmaceutical companies, top cancer centers and scientists, the U.S. Food and Drug Administration, and a leading-edge genomics company that is focused on bringing novel, targeted therapies to AML patients faster. The Beat AML trial protocol employs advanced genomic technology to identify cancer-driving genomic mutations in newly diagnosed patients ages 60 and older and matches them with an investigational drug suited to their AML subtype. In the latest trial, which involves more than two hundred patients in ten studies at eight cancer centers, including Memorial Sloan Kettering Cancer Center, Ohio State University, and the OHSU Knight Cancer Institute, the genetic analysis is being completed in seven days, an unprecedented timeframe in genomic technology.
The late Harry T. Mangurian, Jr. was a successful businessman and owner of the Boston Celtics who died of AML in 2008. Every year, more than twenty thousand Americans are diagnosed with AML and ten thousand AML patients die. In addition to its latest gift, the Mangurian Foundation previously donated $9 million in support of LLS's Beat AML initiatives.
"This significant gift from the Harry T. Mangurian Jr. Foundation has the power to transform and will accelerate LLS's efforts to advance the science and treatment for patients with this deadly cancer by revolutionizing how AML is studied and treated," said LLS president and CEO Louis J. DeGennaro. "The generosity of the Mangurian Foundation, and their long-term commitment to our quest to cure AML cannot be overstated. Not only is it a testament to their confidence in us to make a real impact on patients, but it demonstrates the value of 'investing' with LLS as our efforts are paying off for patients today. We need this kind of support now, more than ever, as sources of funds for innovative medical research are harder to come by."
(Image credit: Getty Images)